This HTML5 document contains 36 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB05219/identifier/drugbank/

Statements

Subject Item
n2:DB05219
rdf:type
n3:Drug
n3:description
AN2728 is a novel oxaborole in development for the topical treatment of psoriasis. Since psoriasis pathology includes an overproduction of pro-inflammatory and T-cell-produced cytokines, a small molecule that inhibits production of these cytokines without non-specifically inhibiting cellular functions, such as AN2728, is desirable.
n3:group
investigational
n3:indication
Intended for the treatment of psoriasis.
owl:sameAs
n7:DB05219
dcterms:title
AN2728
adms:identifier
n9:DB05219
n3:mechanismOfAction
AN2728 is the product of a focused medicinal chemistry effort to create small molecules that inhibit TNF-alpha, the inflammatory cytokine that is the target of the powerful monoclonal antibodies now marketed for the treatment of psoriasis. Company researchers have shown that AN2728 suppresses the phosphodiesterase 4 (PDE4) enzyme, leading to TNF-alpha inhibition.
n3:IUPAC-Name
n4:271B6530-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6536-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6535-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6532-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6533-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6534-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B652E-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B652C-363D-11E5-9242-09173F13E4C5 n4:271B652F-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B652D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B653C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B653D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6537-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6538-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B653A-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6539-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B653B-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:category
n3:Bioavailability
n4:271B6542-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6544-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6545-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6541-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6540-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6543-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6531-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B653E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B653F-363D-11E5-9242-09173F13E4C5